Point Biopharma Global Stock Z Score
PNTDelisted Stock | USD 9.06 0.10 1.09% |
POINT |
POINT Biopharma Global Company Z Score Analysis
POINT Biopharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, POINT Biopharma Global has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
All Next | Launch Module |
POINT Fundamentals
Return On Equity | 0.26 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.40 % | |||
Operating Margin | (10.62) % | |||
Current Valuation | 1 B | |||
Shares Outstanding | 106.57 M | |||
Shares Owned By Insiders | 14.97 % | |||
Shares Owned By Institutions | 48.91 % | |||
Number Of Shares Shorted | 2.64 M | |||
Price To Book | 3.13 X | |||
Price To Sales | 5.45 X | |||
Revenue | 226.58 M | |||
EBITDA | 127.32 M | |||
Net Income | 98.29 M | |||
Cash And Equivalents | 199.43 M | |||
Cash Per Share | 2.21 X | |||
Total Debt | 3.56 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 10.90 X | |||
Book Value Per Share | 4.01 X | |||
Cash Flow From Operations | 183.52 M | |||
Short Ratio | 0.98 X | |||
Earnings Per Share | 1.10 X | |||
Target Price | 12.5 | |||
Number Of Employees | 129 | |||
Beta | -0.003 | |||
Market Capitalization | 1.33 B | |||
Total Asset | 578.32 M | |||
Retained Earnings | 39.01 M | |||
Working Capital | 451.08 M | |||
Net Asset | 578.32 M |
About POINT Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze POINT Biopharma Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of POINT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of POINT Biopharma Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |